Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis.

Diagnosis Drug allergy Drug hypersensitivity Prediction

Journal

Toxicological sciences : an official journal of the Society of Toxicology
ISSN: 1096-0929
Titre abrégé: Toxicol Sci
Pays: United States
ID NLM: 9805461

Informations de publication

Date de publication:
08 Apr 2024
Historique:
medline: 8 4 2024
pubmed: 8 4 2024
entrez: 8 4 2024
Statut: aheadofprint

Résumé

Drug hypersensitivity reactions (DHRs) are a type of adverse drug reaction that can occur with different classes of drugs and affect multiple organ systems and patient populations. DHRs can be classified as allergic or non-allergic based on the cellular mechanisms involved. Whereas non-allergic reactions rely mainly on the innate immune system, allergic reactions involve the generation of an adaptive immune response. Consequently, drug allergies are DHRs for which an immunological mechanism, with antibody and/or T cell, is demonstrated. Despite decades of research, methods to predict the potential for a new chemical entity to cause DHRs or to correctly attribute DHRs to a specific mechanism and a specific molecule are not well-established. This review will focus on allergic reactions induced by systemically administered low molecular weight (LMW) drugs with an emphasis on drug- and patient-specific factors that could influence the development of DHRs. Strategies for predicting and diagnosing DHRs, including potential tools based on the current state of the science, will also be discussed.

Identifiants

pubmed: 38588579
pii: 7642413
doi: 10.1093/toxsci/kfae046
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the Society of Toxicology.

Auteurs

Marc Pallardy (M)

Université Paris-Saclay, INSERM, Inflammation Microbiome Immunosurveillance, Orsay, France.

Rami Bechara (R)

Université Paris-Saclay, INSERM, CEA, Center for Research in Immunology of Viral, Autoimmune, Hematological and Bacterial Diseases (IMVA-HB), Le Kremlin Bicêtre, France.

Jessica Whritenour (J)

Pfizer Worldwide Research, Development and Medical, Groton, CT, USA.

Shermaine Mitchell-Ryan (S)

The Health and Environmental Science Institute, Immunosafety Technical Committee, Washington, DC, USA.

Danuta Herzyk (D)

Merck & Co., Inc, West Point, Pennsylvania, USA.

Herve Lebrec (H)

Amgen Inc., Translational Safety and Bioanalytical Sciences, South San Francisco, CA, USA.

Hans Merk (H)

Department of Dermatology and Allergology, RWTH Aachen University, Aachen, Germany.

Ian Gourley (I)

Janssen Research & Development, LLC, Immunology Clinical Development, Spring House, PA, USA.

Wendy J Komocsar (WJ)

Immunology Business Unit, Eli Lilly and Company, Indianapolis, IN, USA.

Joseph R Piccotti (JR)

Drug Discovery, Schrodinger, Inc, San Diego, CA, USA.

Mercedesz Balazs (M)

Genentech, Biochemical and Cellular Pharmacology, South San Francisco, CA, USA.

Amy Sharma (A)

Pfizer, Drug Safety Research & Development, New York, USA.

Dana B Walker (DB)

Novartis Institute for Biomedical Research, Preclinical Safety- Translational Immunology and Clinical Pathology, Cambridge, MA, USA.

Daniel Weinstock (D)

Janssen Research & Development, LLC, Preclinical Sciences Translational Safety, Spring House, PA, USA.

Classifications MeSH